MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance

MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance - 24/7 Wall St. S&P 5006,362.40 -2.11% Dow Jones45,108.10 -2.16% Nasdaq 10023,104.20 -2.34% Russell 20002,443.51 -2.47% SPDR S&P Biotech ETF (XBI) holds 150+ equal-weight positions and is up 46% over the past year, but faces near-term headwinds from FDA staffing cuts that could slow the regulatory approval pipeline that biotech valuations depend on. Moderna (MRNA) is the largest position at 2.3% weight and expects phase 3 norovirus and m ...